Full Text View
Tabular View
Study Results
Related Studies
Compliance to Synagis (Palivizumab) Under Daily Pediatrician´s Conditions in Premature Infants 33 - 35 wGA
This study has been completed.
Study NCT01077271   Information provided by Abbott

First Received on February 25, 2010.   Last Updated on August 20, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Premature Infants
Additional drug interventions recognized in this trial
Palivizumab
More general drug interventions related to this trial
Anti-Infective Agents
Antiviral Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Abbott
Assign Group Data Management Biostatistics


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services